



# GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.  
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557  
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

Date: 14.02.2023

To,  
The General Manager,  
Listing Department,  
Bombay Stock Exchange  
1<sup>st</sup> Floor, New trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai-400001

Dear Sir/Madam,

Sub: Financial Results for quarter ended 31.12.2022-Regulation 33

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting through Video Conferencing held on Tuesday, 14<sup>th</sup> February, 2023 at 11:30 A.M, interalia considered and approved the unaudited Financial Results for the quarter ended 31<sup>st</sup> December, 2022

Copy of Unaudited Financial Results for the quarter ended 31st December, 2022 is enclosed herewith

Kindly take the same on record and acknowledge the receipt of same.

Thanking You  
For Godavari Drugs Limited

Mohit Jaju  
Wholetime Director & CFO





**GODAVARI DRUGS LIMITED**

CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2022**  
(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Nine Months ended on		Year ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	3915.81	4054.71	3375.74	12225.51	11682.59	16110.62
2	Other Income	29.86	13.20	5.30	49.73	16.05	27.63
3	<b>Total Revenue from operations (1+2)</b>	<b>3945.67</b>	<b>4067.91</b>	<b>3381.04</b>	<b>12275.24</b>	<b>11698.64</b>	<b>16138.25</b>
4	<b>Expenses</b>						
	(a) Cost of materials consumed	2735.08	3662.06	2047.23	10,286.77	9000.59	12797.36
	Changes in inventories of finished goods & work-in-progress	475.32	-371.12	639.74	-362.92	354.49	248.19
	(c) Employee benefits expense	119.69	113.93	130.56	350.40	380.99	495.65
	(d) Depreciation & amortization expense	51.42	47.25	43.37	144.77	127.65	169.64
	(e) Finance Costs	109.92	105.69	73.30	289.79	223.08	284.93
	(f) Other Expenses	358.80	393.06	299.69	1227.42	1088.02	1440.43
	<b>Total expenses</b>	<b>3850.23</b>	<b>3950.89</b>	<b>3233.90</b>	<b>11936.23</b>	<b>11174.82</b>	<b>15436.20</b>
5	<b>Profit before exceptional Items and tax (3-4)</b>	<b>95.44</b>	<b>117.02</b>	<b>147.14</b>	<b>339.01</b>	<b>523.81</b>	<b>702.06</b>
6	Exceptional items						
7	<b>Profit before Tax (5-6)</b>	<b>95.44</b>	<b>117.02</b>	<b>147.14</b>	<b>339.01</b>	<b>523.81</b>	<b>702.06</b>
8	Tax expense	-28.53	-30.63	-13.92	-93.56	-126.03	-177.53
9	<b>Net Profit for the period (7-8)</b>	<b>66.91</b>	<b>86.39</b>	<b>133.22</b>	<b>245.45</b>	<b>397.78</b>	<b>524.53</b>
10	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to (i) profit or loss						
	Income tax relating to Items that will not (ii) be reclassified to profit or loss						
	Items that will be reclassified to profit (iii) or loss						
	Income tax relating to Items that will be (iv) reclassified to profit or loss						
11	<b>Total Comprehensive Income (9+10)</b>	<b>66.91</b>	<b>86.39</b>	<b>133.22</b>	<b>245.45</b>	<b>397.78</b>	<b>524.53</b>
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity(Reserves and Surplus)						2210.09
14	<b>Earnings per share (of Rs.10/- each ) (not annualized)</b>						
	(a) Basic	0.89	1.15	1.77	3.26	5.28	6.97
	(b) Diluted	0.89	1.15	1.77	3.26	5.28	6.97

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14.02.2023
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.



For GODAVARI DRUGS LIMITED

*(Signature)*  
Mohit Jaju  
CFO  
DIN: 03405414

Place :Secunderabad  
Date : 14-02-2023



**Auditor's Report on Standalone Quarterly and nine month period Unaudited Financial Results  
of Godavari Drugs Limited, Secunderabad, Telangana, pursuant to Regulation 33 of SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

To,


The Board of Directors  
Godavari Drugs Limited  
Secunderabad.

We have reviewed the accompanying statement of unaudited standalone financial results of Godavari Drugs Limited for the third quarter and nine months ended 31<sup>st</sup> December, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,  
Chartered Accountants  
FRN: 000278S

  
Ayyadevara Srinivas  
Proprietor  
ICAI Membership No. 028803  
14/02/2023 : Hyderabad  
UDIN: 23028803BGZHJO2230

